FDA Approval Insights: Selinexor in Relapsed/Refractory DLBCL

Season 3 Episode 50  ·  Oct 26, 2020, 08:50 PM

Headliner
Share
Subscribe

In our exclusive interview, Brian T. Hill, MD, PhD, provides perspective on the FDA approval of selinexor in DLBCL.

Share
Subscribe
Next
Raez on the Rise of Liquid Biopsy in Lung Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air